US cannabis rescheduling could eventually lead to companies saving around $2bn a year in federal taxes, a recent cannabis economics report claims.
Recommendations from the US Department of Health and Human Services (HHS) to reschedule cannabis to schedule III under the US Controlled Substances Act are likely to eventually allow businesses to deduct their business expenses on their federal tax returns.